adg1 Antibody

What is ADG1 Antibody and how was it engineered?

ADG1 is a monoclonal antibody developed through a directed evolution approach to enhance neutralization breadth and potency against sarbecoviruses. It was created by isolating antibodies from a 2003 SARS-CoV survivor, introducing diversity into these antibodies using yeast display libraries, and screening for binding to SARS-CoV-2 . ADG1 represents one of three engineered antibodies (ADG-1, ADG-2, and ADG-3) developed through this process, with each exhibiting different binding and neutralization profiles .

The engineering process involved:

• Isolation of antibodies from SARS-CoV survivors

• Introduction of diversity through yeast display libraries

• Screening for cross-reactive binding to multiple coronaviruses

• Affinity maturation to enhance potency and breadth

• Selection based on neutralization capacity against multiple viral strains

What viral strains can ADG1 effectively neutralize?

ADG1 demonstrates a specific neutralization profile among sarbecoviruses. Based on experimental data, ADG1 potently neutralizes SARS-CoV-2, SARS-CoV, and WIV1, but notably lacks activity against SHC014 . This selective neutralization profile distinguishes it from other antibodies in the ADG series, particularly ADG-2 which demonstrates broader neutralization capacity.

The following table summarizes the neutralization capacity of ADG1 against various sarbecoviruses:

How does ADG1 compare to other antibodies in the ADG series?

Among the three engineered antibodies in the series, ADG-2 emerged as the lead therapeutic candidate due to its superior neutralization breadth and potency. Comparing the three antibodies:

• ADG-1: Potently neutralizes SARS-CoV-2, SARS-CoV, and WIV1, but lacks activity against SHC014

• ADG-2: Displays strong binding to a large panel of sarbecovirus receptor binding domains and neutralizes representative epidemic sarbecoviruses with remarkable potency, including SARS-CoV-2, SARS-CoV, SHC014, and WIV1

• ADG-3: Cross-neutralizes multiple sarbecoviruses but with markedly lower potency than ADG-2

ADG-2 demonstrates IC50 values between 4-8 ng/ml against SARS-CoV and two bat SARS-related viruses, making it significantly more potent as a pan-sarbecovirus neutralizing antibody compared to ADG-1 .

What is the structural basis for ADG1's binding specificity?

While detailed structural information specifically for ADG1 is limited in the provided search results, insights can be drawn from structural studies on ADG-2, which belongs to the same antibody series. ADG-2 employs a distinct angle of approach to recognize a highly conserved epitope that overlaps the receptor binding site of sarbecoviruses . This epitope represents a vulnerability for clade 1 sarbecoviruses.

The binding specificity of these antibodies relates to their recognition of:

• Conserved residues in the receptor binding domain (RBD)

• Epitopes that overlap with the ACE2 receptor binding site

• Structural elements that are maintained across multiple sarbecovirus strains

Researchers investigating ADG1's binding specificity should consider conducting:

• X-ray crystallography studies of ADG1-RBD complexes

• Cryo-EM analysis to determine the precise binding interface

• Epitope mapping through site-directed mutagenesis

What methodologies are recommended for assessing ADG1's binding kinetics?

Based on the methodologies used for similar antibodies, researchers should consider the following approaches to evaluate ADG1's binding kinetics:

• Surface Plasmon Resonance (SPR): Using instruments such as Biacore T200, researchers can determine kinetic rate constants for binding. The protocol should include:

  • Immobilizing goat anti-human IgG (Fc specific) on a CM5 sensor chip using amine coupling chemistry

  • Capturing ADG1 on the sensor chip at approximately 10 μg/mL

  • Injecting the target receptor binding domains at concentrations ranging from 1.56-100 nM

  • Regenerating the bound complex using a pH 1.5 Glycine buffer

  • Analyzing data using the instrument's evaluation software

• Cell-based binding assays:

  • Isolating PBMCs and stimulating target expression

  • Staining with specific antibodies for analysis

  • Exposing cells to ADG1 at concentrations ranging from 100 nM to 0.015 nM with 3-fold serial dilutions

  • Analyzing binding using flow cytometry

These methodologies allow for precise determination of association and dissociation rates, as well as equilibrium binding constants.

How can researchers evaluate the potential for viral escape mutations against ADG1?

Evaluating viral escape potential is critical for antibody development. Researchers should consider the following methodological approaches:

• Serial passage experiments:

  • Culture virus in the presence of sub-neutralizing concentrations of ADG1

  • Progressively increase antibody concentration over multiple passages

  • Sequence viral populations after each passage to identify emerging mutations

  • Test neutralization efficacy against escape variants

• Deep mutational scanning:

  • Generate libraries of RBD mutants

  • Screen for variants that maintain ACE2 binding but escape ADG1 neutralization

  • Map escape mutations to the antibody epitope

• Structural analysis:

  • Identify epitope residues through crystallography or cryo-EM

  • Perform computational prediction of mutation impact on binding

  • Validate predictions through site-directed mutagenesis and binding studies

• Natural variant testing:

  • Evaluate neutralization potency against a panel of naturally occurring variants

  • Identify variants with reduced susceptibility to ADG1

  • Correlate reduced susceptibility with specific mutations

What in vitro assays are most appropriate for evaluating ADG1's neutralization capacity?

Several complementary assays can be employed to comprehensively assess ADG1's neutralization capacity:

• Pseudovirus neutralization assays:

  • MLV (murine leukemia virus) pseudotyped with SARS-CoV-2 or other sarbecovirus spike proteins

  • VSV (vesicular stomatitis virus) pseudotyped systems

  • Advantages: BSL-2 containment, high throughput, quantitative readout

• Authentic virus neutralization assays:

  • Plaque reduction neutralization tests (PRNT)

  • Focus reduction neutralization tests (FRNT)

  • Luciferase reporter viruses (e.g., SARS-CoV-2-nLuc)

  • Advantages: physiologically relevant, accounts for all viral proteins

• RBD-ACE2 binding inhibition assays:

  • ELISA-based competition assays

  • Cell-based receptor competition assays

  • Advantages: mechanistic insight, BSL-1 containment

For representative results, researchers should test against multiple viral strains, including:

• SARS-CoV-2 (including the D614G variant and other variants of concern)

• SARS-CoV

• Bat SARS-like viruses (WIV1, SHC014)

What are the recommended in vivo models for testing ADG1 efficacy?

Based on successful models used for ADG-2, researchers should consider the following in vivo approaches:

• Mouse-adapted virus models:

  • SARS-CoV (MA15) and SARS-CoV-2 (MA10) mouse-adapted strains in Balb/c mice

  • Challenge dose: 10³ plaque-forming units (PFU) via intranasal route

  • Antibody administration: intraperitoneal injection (200 μg dose demonstrated efficacy with ADG-2)

• Experimental design considerations:

  • Prophylactic administration: 12 hours before viral challenge

  • Therapeutic administration: 12 hours post-infection

  • Daily monitoring of weight loss and respiratory function (Penh measurement)

  • Assessment of viral load in lungs at day 2 and 4 post-infection

  • Histopathological analysis of lung tissue

• Readouts to evaluate:

  • Weight loss progression

  • Enhanced pause (Penh) as a measure of airway resistance

  • Viral replication in the lungs (quantified via plaque assay or qPCR)

  • Gross and microscopic lung pathology

This experimental approach allows for comprehensive assessment of both prophylactic and therapeutic efficacy in physiologically relevant models .

How can researchers assess potential off-target effects or polyspecificity of ADG1?

Evaluating potential off-target binding and polyspecificity is crucial for antibody development. Recommended methodologies include:

• Polyspecificity assays:

  • Validated assays predictive of serum half-life in humans

  • Assessment of binding to a panel of unrelated proteins

  • Evaluation against tissue cross-reactivity panels

• Biophysical characterization:

  • Hydrophobicity assessment

  • Self-interaction propensity measurement

  • Thermal stability analysis

• In vivo toxicology:

  • Single and repeat-dose studies in relevant species

  • Complete blood counts and chemistry panels

  • Histopathological examination of major organs

From the available data, ADG-1 demonstrated favorable biophysical properties:

• Lack of polyreactivity in predictive assays

• Low hydrophobicity

• Low propensity for self-interaction

• Thermal stability within the range observed for clinically approved antibodies

These properties suggest low risk for poor pharmacokinetic behavior and indicate that the process of in vitro engineering did not negatively impact biophysical properties linked to downstream behaviors such as serum half-life, manufacturing ease, and long-term stability .

How does ADG1 compare to clinical-stage SARS-CoV-2 neutralizing antibodies?

• Neutralization breadth:

  • ADG-1 neutralizes multiple viruses (SARS-CoV-2, SARS-CoV, WIV1)

  • Many clinical-stage antibodies are specific to SARS-CoV-2 only

  • S309 (precursor to sotrovimab) shows cross-neutralization but with lower potency than ADG-2

• Epitope considerations:

  • Many clinical antibodies target highly variable epitopes among sarbecoviruses

  • This limits their neutralization breadth and increases susceptibility to escape mutations

  • The epitope recognized by the ADG series appears to be more conserved

Researchers working with ADG-1 should consider head-to-head comparisons with clinical antibodies using standardized neutralization assays to precisely determine relative potencies.

What approaches can be used to further engineer ADG1 for enhanced properties?

Based on the successful engineering of the ADG antibody series, researchers could consider the following approaches to further enhance ADG1:

• Directed evolution strategies:

  • Additional rounds of yeast display selection with diversified libraries

  • Selection against panels of diverse RBDs to enhance cross-reactivity

  • Negative selection against undesired targets to improve specificity

• Structure-guided design:

  • Based on crystal structures of antibody-RBD complexes

  • Targeted mutations in the CDR regions to enhance binding affinity

  • Framework modifications to improve stability

• Fc engineering:

  • Modification of Fc domain to enhance effector functions

  • Half-life extension through Fc mutations (e.g., YTE mutations)

  • Tailoring of Fc-mediated activities based on therapeutic goals

• Bispecific formats:

  • Combining ADG1 binding specificity with other complementary binding domains

  • Targeting multiple epitopes to reduce escape potential

  • Enhancing breadth by incorporating binding domains with complementary coverage

Each approach should be followed by comprehensive characterization of binding, neutralization, biophysical properties, and in vivo efficacy to ensure that improvements in one property do not compromise others.

How should researchers design experiments to evaluate ADG1 against emerging variants?

A comprehensive experimental design for evaluating ADG1 against emerging variants should include:

• Binding studies:

  • ELISA against variant RBD proteins

  • Bio-layer interferometry or SPR for kinetic analysis

  • Cell-surface binding to variant spike-expressing cells

• Neutralization assays:

  • Pseudovirus neutralization with variant spike proteins

  • Authentic variant virus neutralization where available

  • Comparative IC50 determination across variants

• Escape mutation mapping:

  • Deep mutational scanning focused on epitope residues

  • Assessment of neutralization against combinatorial mutants

  • Computational prediction of mutation impact

• In vivo evaluation:

  • Challenge studies with variant viruses in appropriate animal models

  • Comparative prophylactic and therapeutic efficacy

  • Pharmacokinetic/pharmacodynamic studies with variants

• Data analysis approach:

  • Fold-change in IC50 relative to reference strain

  • Correlation of neutralization potency with binding affinity

  • Structure-based interpretation of variant impact

This systematic approach allows for comprehensive characterization of ADG1's activity against emerging variants and identification of potential vulnerabilities.

What controls and benchmarks should be included when evaluating ADG1?

To ensure robust and reproducible results when evaluating ADG1, researchers should include:

• Antibody controls:

  • Isotype-matched control antibody (e.g., human IgG4)

  • Well-characterized SARS-CoV-2 neutralizing antibodies (e.g., S309)

  • ADG-2 as a benchmark within the same antibody series

• Assay controls:

  • Positive control sera from convalescent or vaccinated individuals

  • Negative control sera from pre-pandemic samples

  • Technical replicates and inter-assay controls for normalization

• Viral strain benchmarks:

  • Original Wuhan SARS-CoV-2 strain as reference

  • D614G variant which became globally dominant

  • Panel of representative sarbecoviruses (SARS-CoV, WIV1, SHC014)

• Quality control parameters:

  • Antibody purity assessment (>95% by SEC-HPLC)

  • Endotoxin testing (<0.5 EU/mg)

  • Aggregation analysis by dynamic light scattering

Including these controls and benchmarks ensures that results can be meaningfully compared across studies and laboratories, facilitating reproducibility and reliable data interpretation.